G250-scFV-transduced autologous T-lymphocyte cell therapy (Daniel den Hoed Cancer Center)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameG250-scFV-transduced autologous T-lymphocyte cell therapy (Daniel den Hoed Cancer Center)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionCarbonic anhydrase IX modulators

TargetsCarbonic anhydrase IX

Therapy Area/IndicationsCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesErasmus University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesErasmus University

Active IndicationsN/A

Inactive IndicationsCarcinoma, Renal Cell

Other Information

ATC CodeN/A